6ECQ image
Entry Detail
PDB ID:
6ECQ
Keywords:
Title:
The human methylenetetrahydrofolate dehydrogenase/cyclohydrolase (FolD) complexed with NADP and inhibitor LY345899
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2018-08-08
Release Date:
2019-03-27
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.24
R-Value Work:
0.17
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:METHYLENETETRAHYDROFOLATE DEHYDROGENASE CYCLOHYDROLASE
Chain IDs:A, B
Chain Length:296
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
An assessment of three human methylenetetrahydrofolate dehydrogenase/cyclohydrolase-ligand complexes following further refinement.
Acta Crystallogr F Struct Biol Commun 75 148 152 (2019)
PMID: 30839287 DOI: 10.1107/S2053230X18018083

Abstact

The enzymes involved in folate metabolism are key drug targets for cell-growth modulation, and accurate crystallographic structures provide templates to be exploited for structure-based ligand design. In this context, three ternary complex structures of human methylenetetrahydrofolate dehydrogenase/cyclohydrolase have been published [Schmidt et al. (2000), Biochemistry, 39, 6325-6335] and potentially represent starting points for the development of new antifolate inhibitors. However, an inspection of the models and the deposited data revealed deficiencies and raised questions about the validity of the structures. A number of inconsistencies relating to the publication were also identified. Additional refinement was carried out with the deposited data, seeking to improve the models and to then validate the complex structures or correct the record. In one case, the inclusion of the inhibitor in the structure was supported and alterations to the model allowed details of enzyme-ligand interactions to be described that had not previously been discussed. For one weak inhibitor, the data suggested that the ligand may adopt two poses in the binding site, both with few interactions with the enzyme. In the third case, that of a potent inhibitor, inconsistencies were noted in the assignment of the chemical structure and there was no evidence to support the inclusion of the ligand in the active site.

Legend

Protein

Chemical

Disease

Primary Citation of related structures